A preponderance of zeros may occur with several types of data. With interval data one may have a large proportion of actual zero values. For example, if income is the response being modeled, there could be many subjects with no income. With ordinal data one may be faced with the problem that most subjects have all zero values. If adverse event data is being modeled and 0 reflects no adverse event, then one might have a large fraction of subjects with all zero values. PRI in conjunction with several pharmaceutical companies has been exploring ways to model such responses. These include altered zero, added zero, mover-stayer, and sojourn models to name a few.

Big development for Dr. Mould, she has been invited to join the editorial review board for Clinical Pharmacology & Therapeutics. It is an honor she has proudly accepted. Congratulations Dr. Mould!

Dear Dr. Mould,

With the 2007 transition both in editorial leadership and publisher (Nature) complete, the principle journal for the discipline of pharmacology, Clinical Pharmacology & Therapeutics, is now moving forward with other initiatives to improve the journal, which includes building the Editorial Board.

Comprised of ~60 subject matter experts across the fields of pharmacology and clinical pharmacology, the Editorial Board serves as the backbone for the high quality content of the journal. We are populating the Editorial Board with experts from academia, government, and pharma, while maintaining diversity to reflect the demographics in authors and readership.

We believe your participation on the Editorial Board is important to its future success and invite you to join this outstanding team of experts. Your responsibilities would include reviewing ~10 manuscripts each year, providing topical and authorial suggestions for contributions to the journal, contributing articles on occasion to the journal, and participating in the Editorial Board Meeting at the annual ASCPT meeting.

I hope you will be willing to share your expertise and serve the Journal, the Society, and the discipline by joining the Journal s Editorial Board. I would be happy to discuss this invitation in more detail and ask that you contact me if you have any questions or concerns.

Warmest regards,
Elise Laffman-Johnson
Managing Editor
Clinical Pharmacology & Therapeutics